Natural Antibiotic Susceptibility of Proteus spp., with Special Reference to P. mirabilis and P. penneri Strains

References

• Wenner JJ, Rettger LF. A systematic study of the Proteus group of bacteria. J Bacteriol 1919; 4: 331–53.
   PubMedGoogle Scholar
• Hauser G. [Uber Faulnisbakterien und deren Beziehungen zur Septikamie. Ein Beitrag zur Morphologie der Spaltpilze.] 1885. Vogel, Leipzig, Germany. (Article in German)
   Google Scholar
• Cosenza BJ, Podgwaite JD. A new species of Proteus isolated from larvae of the gypsy moth Porthetria dispar (L.). Antonie van Leeuw. J Microbiol Serol 1966; 32: 187–91.
   PubMed Web of Science ®Google Scholar
• Hickman FW, Steigerwalt AG, Farmer JJ III, Brenner DJ. Identification of Proteus penneri sp. nov., formerly known as Proteus vulgaris indole negative or as Proteus vul-garis biogroup 1. J Clin Microbiol 1982; 15: 1097–102.
   Google Scholar
• Brenner DJ, Hickman-Brenner FW, Holmes B, Hawkey PM, Penner JL, Grimont PAD, Mohr O'Hara C. Replacement of NCTC 4175, the current type strain of Proteus vulgaris, with ATCC 29905. Request for an opinion. Int J Syst Bacteriol 1995; 45: 870–1.
   PubMedGoogle Scholar
• Mohr O'Hara C, Benner FW, Steigerwalt AG, Hill BC, Holmes B, Grimont PAD, Hawkey PM, Penner JL, Miller JM, Brenner DJ. Classification of Proteus vulgaris biogroup 3 with recognition of Proteus hauseri sp. nov., nom. rev, and unnamed Proteus genomospecies 4, 5 and 6. Int J Syst Evolut Microbiol 2000; 50: 1869–75.
   Google Scholar
• Janda JM, Abbott SL, Khashe S, Probert W. Biochemical identification and characterization of DNA groups within the Proteus vulgaris complex. J Clin Microbiol 2001; 39: 1231–4.
   PubMed Web of Science ®Google Scholar
• Mohr O'Hara C, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000; 13: 534–46.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) report, data summa-ry October 1986-April 1996, issued May 1996. Am J Infect Control 1996; 24: 381.
   Google Scholar
• Stamm WE. Urinary tract infections. In: Root RK, editor. Clinical infectious diseases: a practical approach. Oxford Univeristy Press, Inc., New York, N.Y. 1999: 649-56.
   Google Scholar
• Agro AS, Garner ET, Wright JW III, Caballeros de Escobar I, Villeda B, Seidlin M. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20: 744–59.
   Google Scholar
• Obi CL, Enweani IB, Giwa JO. Bacterial agents causing chronic suppurative otitis media. Est Afr Med J 1995; 72: 370–2.
   PubMed Web of Science ®Google Scholar
• de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 2000; 45: 537–9.
   PubMed Web of Science ®Google Scholar
• Watanakunakorn C, Perni SC. Proteus mirabilis bac-teremia: a review of 176 cases during 1980-1992. Scand J Infect Dis 1994; 26: 361–7.
   PubMed Web of Science ®Google Scholar
• Lam DS, Kwok AK, Chew S. Post-keratoplasty endoph-thalmitis caused by Proteus mirabilis. Eye 1998; 12: 139–40.
   PubMed Web of Science ®Google Scholar
• Chou ML, Wang HS, Huang SC, Lee N. Neonatal meningitis due to Proteus mirabilis: report of 3 cases. Changgeng Yi Xue Za Zhi 1988; 11: 66–73.
   PubMedGoogle Scholar
• Grahnquist L, Lundberg B, Tullus K. Neonatal Proteus meningoencephalitis. Case report. Acta Pathol Microbiol Immunol Scand 1992; 100: 734–6.
   PubMed Web of Science ®Google Scholar
• Corredoira JM, Ariza J, Pallares R, Carratala J, Viladrich PF, Rufi G, Verdaguer R, Gudiol F. Gram-negative bacillary cellulitis on patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis 1994; 13: 19–24.
   PubMed Web of Science ®Google Scholar
• Ananthasubramaniam K, Karthikeyan V. Aortic ring abscess and aortoatrial fistula complicating fulminant prostetic valve endocarditis due to Proteus mirabilis. J Ultrasound Med 2000; 19: 63–6.
   PubMed Web of Science ®Google Scholar
• Go C, Bernstein JM, de Jong AL, Sulek M, Friedman EM. Intracranial complications of acute mastoiditis. Int J Pediatr Otorhinolaryngol 2000; 52: 143–8.
   PubMed Web of Science ®Google Scholar
• Marx AC, Hartshorne MF, Stull MA, Truwit CL. Case report 496: intrasseous gas in Proteus mirabilis osteomyelitis complicating bone infarcts in sickle cell disease. Skeletal Radiol 1988; 17: 510–3.
   PubMed Web of Science ®Google Scholar
• Carre M, Sarlangue J, Baronnet R, Nicolau A, Demarquez JL. [Cerebral abscess caused by Proteus mirabilis in the neonatal period.] Arch Fr Pediatr 1987; 44: 871-4. (Article in French)
   Google Scholar
• Francois A, Berterottiere D, Aigrain Y, Tachet F, Ropert JC. [Neonatal Proteus mirabilis adrenal gland abscess]. Arch Fr Pediatr 1991; 48: 559–61. (Article in French)
   PubMedGoogle Scholar
• Kerns SR, Dougherty K, Pope TL, Scheld WM. Septic sacroiliitis due to Proteus mirabilis. South Med J 1990; 83: 589–91.
   PubMed Web of Science ®Google Scholar
• Ojeda-Vargas M, Pacheco A, Elia M, Villaverde R, Baquero F. Proteus mirabilis as a cause of recurrent lung infection in a cystic fibrosis patient. Eur J Clin Microbiol Infect Dis 1990; 9: 234–5.
   PubMed Web of Science ®Google Scholar
• Krajden S, Kuksa M, Petrea C, Crisp II, Penner JL. Expanded clinical spectrum of infections caused by Proteus pen neri. J Clin Microbiol 1987; 25: 578–9.
   PubMed Web of Science ®Google Scholar
• Latuszynski DK, Schoch P, Qadir MT, Cunha BA. Proteus pen neri urosepsis in a patient with diabetes mellitus. Heart Lung 1998; 27: 146–8.
   PubMed Web of Science ®Google Scholar
• Engler HD, Troy K, Bottone EJ. Bacteremia and subcu-taneous abscess caused by Proteus pen neri in a neutropenic host. J Clin Microbiol 1990; 28: 1645–6.
   PubMed Web of Science ®Google Scholar
• Christophersen I, Galiana A, Lopez L, Gonzalez S, Bazet C, Padreira W. [Nosocomial outbreak of Proteus pen-neri infections at a general hospital]. Enferm Infecc Microbiol Clin 1989; 7: 340–1. (Article in Spanish)
   PubMedGoogle Scholar
• Jarlier V, Fosse T, Philippon A, and the ICU study group. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med 1996; 22: 1057–65.
   Google Scholar
• Liu PYF, Gur D, Hall LMC, Livermore DM. Survey of the prevalence of I3-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992; 30: 429–47.
   PubMed Web of Science ®Google Scholar
• Mutnick AH, Turner PJ, Jones RN. Emerging antimi-crobial resistances among Proteus mirabilis in Europe: report from the MYSTIC program (1997-2001). Meropenem Yeraly Susceptibility Test Information Collection. J Chemother 2002; 14: 253–8.
   Google Scholar
• Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J. Prevalence of I3-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hos-pital. Antimicrob Agents Chemother 2000; 44: 1930–5.
   PubMed Web of Science ®Google Scholar
• Stock I, Wiedemann B. [Natural antibiotic susceptibility of Proteus species of the Proteus vulgaris complex]. Chemother J 1997; 6: 76–84. (Article in German)
   Google Scholar
• Stock I, Wiedemann B. [Determination of natural antibi-otic susceptibility]. Chemother J 1998; 7: 127–35. (Article in German)
   Google Scholar
• Stock I, Wiedemann B. Natural antibiotic susceptibility of Providencia stuartii, P. rettgeri, P. alcalifaciens and P. rustigianii strains. J Med Microbiol 1998; 47: 629–42.
   PubMed Web of Science ®Google Scholar
• Deutsches Institut far Normung e.V. DIN document 58940-4, Table 1. Susceptibility testing of pathogens to antimicrobial agents, part 4: Evaluation classes of the mini-mum inhibitory concentration, Supplement 1: MIC break-points of antibacterial agents. Deutsches Institut für Normung e.V. 2000, Berlin, Germany.
   Google Scholar
• Comite de l'Antibiogramme de la Societe Française de Microbiologie. Statement. Pathol Biol 1998; 46: I–XVI.
   Google Scholar
• Olsson-Liljequist B, Larson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. Part 3: method-ology for susceptibility testing. Scand J Infect Dis 1997; 105 (Suppl): 13-23.
   Google Scholar
• National Committee for Clinical Laboratory Standards. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards. 2000, Villanova, Pa.
   Google Scholar
• Troxler R, von Graevenitz A, Funke G, Wiedemann B, Stock I. Natural antibiotic susceptibility of Listeria species: L. grayi, L. innocua, L. ivanovii, L. monocytogenes, L. seel-igeri and L. welshimeri strains. Clin Microbiol Infect 2000; 6: 525–35.
   Google Scholar
• Stock I, Heisig P, Wiedemann B. Expression of I3-lacta-mases in Yersinia enterocolitica strains of biovars 2, 4 and 5. J Med Microbiol 1999; 48: 1023–7.
   PubMed Web of Science ®Google Scholar
• Reger PJ, Mockler DF, Miller MA. Comparison of antimicrobial susceptibility, I3-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol 1993; 39: 273–81.
   PubMed Web of Science ®Google Scholar
• Stock I, Wiedemann B. Natural antibiotic susceptibilities of Edwardsiella tarda, E. ictaluri, and E. hoshinae. Antimicrob Agents Chemother 2001; 45: 2245–55.
   Google Scholar
• Na'was TE, Mawajdeh S, Dababneh A, al-Oman i A. In vitro activities of antimicrobial agents against Proteus species from clinical specimens. Br J Biomed Sci 1994; 51: 95–9.
   PubMed Web of Science ®Google Scholar
• Magalhaes VD, Schuman W, Castilho BA. A new tetra-cycline resistance determinant cloned from Proteus mirabilis. Biochim Biophys Acta 1998; 1443: 262–6.
   PubMed Web of Science ®Google Scholar
• Lukomski S, Pytlos M, Serwecinska L, Sidorczyk Z, Jaworski A. Analysis of antibiotic resistance determinants in Proteus pen neri. Eur J Clin Microbiol Infect Dis 1993; 12: 467–9.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Chow SF. [Urinary tract infections and micro-biological characteristics of Proteus pen neri isolated in Taiwan] Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1987; 20: 132-9. (Article in Chinese)
   Google Scholar
• Charles IG, Harford S, Brookfield JFY, Shaw WV. Resistance to chloramphenicol in Proteus mirabilis by expres-sion of a chromosomal gene for chloramphenicol acetyltrans-ferase. J Bacteriol 1985; 164: 114–22.
   PubMed Web of Science ®Google Scholar
• Alon U, Davidai G, Berant M, Merzbach D. Five-year survey of changing patterns of susceptibility of bacterial uropathogens to trimethoprim-sulfamethoxazole and other antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 126–8.
   PubMed Web of Science ®Google Scholar
• Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211–5.
   PubMed Web of Science ®Google Scholar
• Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J. Chromosomally encoded AmpC I3-lactamase in a clini-cal isolate of Proteus mirabilis. Antimicrob Agents Chemother 1998; 42: 1110–4.
   PubMed Web of Science ®Google Scholar
• Pagani L, Migliavacca R, Pallecchi L, Matti C, Giacobone E, Amicosante G, Romero E, Rossolini GM. Emerging extended-spectrum I3-lactamases in Proteus mirabilis. J Clin Microbiol 2002; 40: 1549–52.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Williams JD. I3-lactams: Mode of action and mechanisms of bacterial resistance. In Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Maryland, 1996: 502-78.
   Google Scholar
• Stock I, Wiedemann B. [Natural antibiotic susceptibility of Yersinia pseudotuberculosis strains]. Chemother J 1999; 8: 219–26. (Article in German)
   Google Scholar
• Livermore DM. I3-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557–84.
   PubMed Web of Science ®Google Scholar
• Aspiotis A, Cullmann W, Dick W, Stieglitz M. Inducible I3-lactamases are principally responsible for the naturally occur-ring resistance towards I3-lactam antibiotics in Proteus vul-garis. Chemotherapy 1996; 32: 236–46.
   Google Scholar
• Kotelko K. Proteus mirabilis: taxonomic position, peculiarities of growth, components of the cell envelope. Curr Top Microbiol Immunol 1986; 129: 181–215.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Tsukamoto K, Sawai T. Nucleotide sequence and characterization of a carbenicillin-hydrolyzing penicillinase gene from Proteus mirabilis. J Bacteriol 1991; 173: 7038–41.
   PubMed Web of Science ®Google Scholar
• Bonnet R, Marchandin H, Chanal C, Sirot D, Labia R, De Champs C, Jumas-Bilak E, Sirot J. Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother 2002; 46: 2004–6.
   PubMed Web of Science ®Google Scholar
• Grace ME, Gregory FJ, Hung PP, Fu KP. Purification and properties of a I3-lactamase from Proteus pen neri. J Antibiot 1986; 39: 938–42.
   PubMed Web of Science ®Google Scholar
• Miro E, Barthelemy M, Peduzzi J, Reynaud A, Morand A, Prats G, Labia R. [Properties of a cephalosporinase pro-duced by Proteus pen neri inhibited by clavulanic acid]. Pathol Biol (Paris) 1994; 42: 487–90. (Article in French)
   PubMed Web of Science ®Google Scholar
• Datz M, Joris B, Azab EA, Galleni M, Van Beeumen J, Frere JM, Martin HH. A common system controls the induc-tion of very different genes. The class-A beta-lactamase of Proteus vulgaris and the enterobacterial class-C beta-lacta-mase. Eur J Biochem 1994; 226: 149–57.
   Google Scholar
• Ishiguro K, Sugimoto K. Purification and characteriza-tion of the Proteus vulgaris BlaA protein, the activator of the beta-lactamase gene. J Biochem 1996; 120: 98–103.
   PubMed Web of Science ®Google Scholar
• Liassine N, Madec S, Ninet B, Metral C, Fouchereau-Peron M, Labia R, Auckenthaler R. Postneurosurgical menin-gitis due to Proteus pen neri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A beta-lacta-mase HugA and its LysR-type regulatory protein HugR. Antimicrob Agents Chemother 2002; 46: 216–9.
   PubMed Web of Science ®Google Scholar
• Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmaco-kinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infec-tions. Drugs 1997; 53: 637–56.
   Google Scholar
• Stock I, Falsen E, Wiedemann B. Moellerella wiscon-sensis: identification, natural antibiotic suscepti-bility and its dependency on the medium applied. Diagn Microbiol Infect Dis 2002; 45: 1–11.
   Web of Science ®Google Scholar
• Stock I, Grtiger T, Wiedemann B. Natural antibiotic sus-ceptibility of strains of the Enterobacter cloacae complex. Int J Antimicrob Agents 2001; 18: 537–45.
   PubMed Web of Science ®Google Scholar
• Stock I, Wiedemann B. Natural antibiotic susceptibility of Enterobacter amnigenus, E. cancerogenus, E. gergouiae and E. sakazakii strains. Clin Microbiol Infect 2002; 8: 564–78.
   PubMed Web of Science ®Google Scholar
• Stock I. Natural antibiotic susceptibility of Enterobacter spp., with special reference to E. aerogenes and E. inter-medius strains. J Chemother 2002; 14, 5: 444-60.
   Google Scholar
• Kresken M, Hafner D, and the study group “Resistance'of the Paul Ehrlich Society for Chemotherapie e.V. [Resistenzsituation bei klinisch wichtigen Infektionserregern gegentiber Chemotherapeutika in Mitteleuropa.] Chemother J 2000; 9: 51-86. (Article in German).
   Google Scholar